Form 4: Cytokinetics Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and sold shares on November 26, 2024.
Summary
- Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, executed a series of transactions on November 26, 2024.
- He exercised 5,300 non-qualified stock options at a price of $7.96 per share.
- Following the exercise, he sold 5,300 shares at $50.17 per share and an additional 2,000 shares at $50.14 per share.
- After these transactions, Mr. Malik directly owns 111,878 shares of Cytokinetics common stock.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider trading activity, with no inherent positive or negative sentiment.
Industry Context
This is a standard SEC Form 4 filing, which is required when company insiders trade their company's stock. It provides transparency into executive transactions.
Comparison to Industry Standards
- Form 4 filings are a common occurrence across all publicly traded companies, and this filing is consistent with standard practices.
- The transactions are typical for executives who receive stock options as part of their compensation.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the sale of shares by an executive.
Key Dates
| Date | Description |
|---|---|
| 03/26/2015 | Date the non-qualified stock options were granted. |
| 11/26/2024 | Date of the stock option exercise and share sales. |
| 02/26/2025 | Expiration date of the non-qualified stock options. |
Keywords
Cytokinetics, stock options, insider trading, executive, share sale, Form 4, CYTK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.